EC approves Alprolix

The European Commission approved Alprolix eftrenonacog alfa to treat and prevent bleeding in hemophilia B patients. Swedish Orphan Biovitrum AB (SSE:SOBI) has rights to the drug from Biogen Inc. (NASDAQ:BIIB) in Europe, North Africa, Russia and 13 Middle Eastern countries.

Alprolix, a recombinant fusion protein consisting of human coagulation Factor IX attached to the Fc domain of human IgG1, is approved in the U.S., Canada, Japan, Australia and New Zealand. ...